KRAS and malignant colon neoplasm: Optimized siRNAs targeting KRAS impaired colon cancer growth in vivo while combinatorial inhibition of KRAS and PIK3CA/PIK3CB significantly improved tumor control compared to single agents alone, demonstrating that targets can be effectively multiplexed (106).